-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Cardiovascular disease (CVD) is the leading cause of death and disability in people with diabetes, and cardiovascular disease risk is associated with higher glycated hemoglobin (HbA1c)
Background: Cardiovascular disease (CVD) is the leading cause of death and disability in people with diabetes, and cardiovascular disease risk is associated with higher glycated hemoglobin (HbA1c)
Conversely, tight glycemic control only later in the course of the disease -- years after type 2 diabetes is diagnosed -- can lead to adverse cardiovascular outcomes
OBJECTIVE: To determine whether early achievement of glycemic control and any subsequent glycemic variability is associated with any change in the risk of major adverse cardiovascular events (MACE)
Materials and methods: A retrospective cohort analysis from the Oxford-Royal General Practitioners Research and Monitoring Centre database - a large UK primary care network
RESULTS: MACE occurred in 2300 of 26180 patients
Table 1 Adjusted MACE hazard ratios in patients with type 2 diabetes
Table 2 Maintain HbA1c ≥ 75 mmol/mol (9.
Table 2 Maintain HbA1c ≥ 75 mmol/mol (9.
CONCLUSIONS: Early control of glycated hemoglobin improves cardiovascular outcomes in patients with type 2 diabetes, although subsequent glycemic changes have negative effects on the individual
CONCLUSIONS: Early control of glycated hemoglobin improves cardiovascular outcomes in patients with type 2 diabetes, although subsequent glycemic changes have negative effects on the individual
Original source: Whyte MB, Joy M, Hinton W, et al.
Early and ongoing stable glycaemic control is associated with a reduction in major adverse cardiovascular events in people with type 2 diabetes: A primary care cohort study.
Diabetes Obes Metab 2022 Apr 04 Early and ongoing stable glycaemic control is associated with a reduction in major adverse cardiovascular events in people with type 2 diabetes: A primary care cohort study.
Leave a comment here